
Aduro Clean Technologies Announces Closing of Underwriter’s Over-Allotment Option in Public Offering

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

ACTFORE Secures Patent for Template Identification and Matching Technology, Transforming Large-Scale Document Analysis in Breach Response



